Literature DB >> 32703344

Correlation between Clinical Factors and Prognosis in Newly Diagnosed Multiple Myeloma.

Xiao-Qing Zhao1, Shu-Ying Zhao1, Wen-Xin Chen1, Xiao-Wei Liu1, Huai-Xiu Yan1, Yong-Ji Lou1.   

Abstract

OBJECTIVE: To explore the correlation between clinical factors and the prognosis of multiple myeloma (MM). STUDY
DESIGN: A cohort study. PLACE AND DURATION OF STUDY: At the Third Affiliated Hospital of Inner Mongolia Medical University, Mongolia from January 2014 to December 2018.
METHODOLOGY: The clinical data of 81 patients with newly diagnosed MM were collected retrospectively. The correlation of prognosis with immunophenotype and (FISH) Fluorescence in situ hybridization was subjected to univariate and multivariate analyses. Overall and progression-free survival was determined.
RESULTS: The overall survival (OS) and progression-free survival (PFS) of patients with CD200+, CD81+, and CD27- were significantly shortened. CD200+ and CD27- were independent prognostic factors for OS and PFS in MM patients. The prognosis-related abnormal genes were analyzed, and univariate analysis revealed that OS and PFS were significantly shortened in patients with RB-1 deletion, CDKN2C deletion, and IGH rearrangement. CDKN2C deletion was an independent prognostic factor for OS and PFS in MM patients.
CONCLUSION: CDKN2C deletion is an independent prognostic factor of MM. CD200+ is an independent risk factor for poor prognosis of MM. Key Words: Multiple myeloma, Prognostic analysis, Fluorescence in situ hybridization, Immunity, Immunophenotype.

Entities:  

Mesh:

Year:  2020        PMID: 32703344     DOI: 10.29271/jcpsp.2020.06.601

Source DB:  PubMed          Journal:  J Coll Physicians Surg Pak        ISSN: 1022-386X            Impact factor:   0.711


  1 in total

1.  Correlations between apparent diffusion coefficient values of WB-DWI and clinical parameters in multiple myeloma.

Authors:  Bei Zhang; Bingyang Bian; Zhiwei Zhao; Fang Lin; Zining Zhu; Mingwu Lou
Journal:  BMC Med Imaging       Date:  2021-06-08       Impact factor: 1.930

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.